Potential Effect of Fisetin in A sample of Obese Diabetic Patients in Iraq

Abstract

Background: Fisetin has been shown previously to attenuate obesity and regulate glucose metabolism in vitro and in vivo. Objective: To assess the potential effect of the dietary supplement (Fisetin) on obese patients with type 2 diabetes. Methods: This randomized, single-blind, controlled study was carried out in Iraq and investigated the effects of 8 weeks of fisetin (100 mg/day) on body weight, BMI, WC, WHR, WHtR, HOMA-IR, and serum levels of fasting glucose, insulin, leptin, adiponectin and creatinine. In this study, 51 Iraqi obese diabetic patients (21 males and 30 females) were randomized into either the fisetin or control group. The fisetin group received fisetin 100 mg/day capsules in combination with their previous treatment, that is metformin (500 mg t.i.d) tablets, while, the control group already received metformin (500 mg t.i.d) tablets in an 8-week trial. Results: there was significant decrease in body weight, BMI, WC, HOMA-IR, serum levels of FBG, insulin and leptin and a significant increase in serum adiponectin level in the fisetin group at the end of the study in comparison with the baseline values. Regarding WHR, WHtR, and serum creatinine they were diminished insignificantly by fisetin supplementation compared with baseline values. However, a significant difference in body weight, BMI, WC, serum levels of FBG, HOMA-IR, leptin and adiponectin was observed in the fisetin group when compared to the control group. The changes in WHR, WHtR, and serum levels of insulin and creatinine were not statistically significant compared to the control group. According to these results, fisetin could aid in the treatment of obesity and improve the diabetic status of obese diabetic patients, suggesting it as a novel complementary anti-obesity agent for these patients and warranting further studies.